South Korea · Delayed Price · Currency is KRW PHARMARESEARCH BIO Statistics
Total Valuation
XKON:217950 has a market cap or net worth of KRW 135.04 billion.
| Market Cap | 135.04B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
XKON:217950 has 4.18 million shares outstanding.
| Current Share Class | 4.18M |
| Shares Outstanding | 4.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 757.83 |
| PB Ratio | -159.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.28
| Current Ratio | 9.28 |
| Quick Ratio | 9.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.51 |
| Interest Coverage | -6.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -162.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.18% in the last 52 weeks. The beta is 0.27, so XKON:217950's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -8.18% |
| 50-Day Moving Average | 35,359.00 |
| 200-Day Moving Average | 34,857.25 |
| Relative Strength Index (RSI) | 28.87 |
| Average Volume (20 Days) | 1,730 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, XKON:217950 had revenue of KRW 178.19 million and -883.52 million in losses. Loss per share was -22,088.06.
| Revenue | 178.19M |
| Gross Profit | 161.36M |
| Operating Income | -759.75M |
| Pretax Income | -883.52M |
| Net Income | -883.52M |
| EBITDA | -755.07M |
| EBIT | -759.75M |
| Loss Per Share | -22,088.06 |
Balance Sheet
The company has 428.99 million in cash and 1.04 billion in debt, giving a net cash position of -614.18 million or -146.91 per share.
| Cash & Cash Equivalents | 428.99M |
| Total Debt | 1.04B |
| Net Cash | -614.18M |
| Net Cash Per Share | -146.91 |
| Equity (Book Value) | -844.19M |
| Book Value Per Share | -21,104.73 |
| Working Capital | 385.15M |
Cash Flow
In the last 12 months, operating cash flow was -386.65 million and capital expenditures -29.10 million, giving a free cash flow of -415.75 million.
| Operating Cash Flow | -386.65M |
| Capital Expenditures | -29.10M |
| Free Cash Flow | -415.75M |
| FCF Per Share | -99.44 |
Margins
| Gross Margin | 90.55% |
| Operating Margin | -426.37% |
| Pretax Margin | -495.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XKON:217950 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.65% |
| FCF Yield | -0.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XKON:217950 has an Altman Z-Score of -6.67 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.67 |
| Piotroski F-Score | 1 |